Skip to main content
. 2021 Jan 16;13(2):319. doi: 10.3390/cancers13020319

Figure 1.

Figure 1

Analyses of CD14−CD56+ cell precursors proliferation and recovery in cultures performed in the absence or in the presence of EZH1/2 inhibitors. (A) Time course analysis shows Ki67 staining in CD14−CD56+ cells undergoing differentiation from UCB-CD34+ in the absence (CTR) or in the presence of GSK126 1 μM (GSK) or UNC1999 1 μM (UNC), between 5 and 14 days of culture. Data obtained from three experiments. (B) The histograms represent the fold change of percentages of CD14−CD56+ cells differentiated in the presence of GSK126 1 μM (GSK) or UNC1999 1 μM (UNC) detectable after 20 days of culture, as compared to CTR condition, arbitrarily normalized to one. Data are expressed as mean values with ± SEM obtained by 10 independent experiments and analyzed by Wilcoxon Signed Rank Test (* p < 0.05; ** p < 0.005).